Close Menu

NEW YORK (GenomeWeb) – NantHealth disclosed Friday after the close of the market that it has received a delisting notice from the Nasdaq Stock Market because its stock price has been below $1 for at least 30 consecutive business days.

The company disclosed this news in a filing with the Securities and Exchange Commission just ahead of the long holiday weekend in the US, though NantHealth said it received the delisting notice two days earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.